Avanza Fonder Ab Intellia Therapeutics, Inc. Transaction History
Avanza Fonder Ab
- $3.37 Trillion
- Q4 2024
A detailed history of Avanza Fonder Ab transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Avanza Fonder Ab holds 36,065 shares of NTLA stock, worth $339,732. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,065Holding current value
$339,732% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding NTLA
# of Institutions
316Shares Held
91.7MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$115 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$90.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$90.4 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$48.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$46.6 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $716M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...